ArticleJournal for immunotherapy of cancer2024

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.

Anna K Maloney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.